BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1591 related articles for article (PubMed ID: 19274989)

  • 21. Evaluation of multidrug therapy with rifampicin, clofazimine and D.D.S. in multibacillary leprosy cases.
    Kundu SK; Hazra SK; Chaudhury S; Chatterjee B
    Indian J Lepr; 1984; 56(1):78-85. PubMed ID: 6548246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results.
    Mane I; Cartel JL; Grosset JH
    Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):224-9. PubMed ID: 9251595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
    Cruz RCDS; Bührer-Sékula S; Penna GO; Moraes MEA; Gonçalves HS; Stefani MMA; Penna MLF; Pontes MAA; Talhari S
    An Bras Dermatol; 2018 Jun; 93(3):377-384. PubMed ID: 29924240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multidrug therapy in leprosy.
    Manglani PR; Arif MA
    J Indian Med Assoc; 2006 Dec; 104(12):686-8. PubMed ID: 17474286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aplastic anaemia associated with multidrug therapy (dapsone, rifampicin and clofazimine) in a patient with lepromatous leprosy.
    Goulart IM; Reis AC; De Rezende TM; Borges AS; Ferreira MS; Nishioka SA
    Lepr Rev; 2005 Jun; 76(2):167-9. PubMed ID: 16038251
    [No Abstract]   [Full Text] [Related]  

  • 26. Adverse effects of multi-drug therapy in leprosy, a two years' experience (2006-2008) in tertiary health care centre in the tribal region of Chhattisgarh State (Bastar, Jagdalpur).
    Singh H; Nel B; Dey V; Tiwari P; Dulhani N
    Lepr Rev; 2011 Mar; 82(1):17-24. PubMed ID: 21644468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antileprosy drugs, pregnancy and fetal outcome.
    Bhargava P; Kuldeep CM; Mathur NK
    Int J Lepr Other Mycobact Dis; 1996 Dec; 64(4):457-8. PubMed ID: 9030117
    [No Abstract]   [Full Text] [Related]  

  • 28. Feasibility of multidrug therapy (MDT) in Hansen's disease in an urban population--Curupaiti State Hospital, Rio de Janeiro, Brazil.
    Andrade VL; Marques AB; da Cunha LH; Avelleira JR
    Int J Lepr Other Mycobact Dis; 1987 Sep; 55(3):435-40. PubMed ID: 3655459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy.
    Villahermosa LG; Fajardo TT; Abalos RM; Cellona RV; Balagon MV; Dela Cruz EC; Tan EV; Walsh GP; Walsh DS
    Am J Trop Med Hyg; 2004 Feb; 70(2):197-200. PubMed ID: 14993633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multidrug therapy regimen for leprosy.
    Firooz A
    J Am Acad Dermatol; 2006 Dec; 55(6):1115; author reply 1115. PubMed ID: 17110233
    [No Abstract]   [Full Text] [Related]  

  • 31. Minocycline is effective and cosmetically preferred to clofazimine by leprosy patients in New York.
    Levis WR; Spencer TI; Ladizinski B
    J Drugs Dermatol; 2010 Aug; 9(8):906. PubMed ID: 20684139
    [No Abstract]   [Full Text] [Related]  

  • 32. Relapse study in smear positive multibacillary (MB) leprosy after 1 year WHO-multi-drug therapy (MDT) in Cebu, Philippines.
    Maghanoy A; Mallari I; Balagon M; Saunderson P
    Lepr Rev; 2011 Mar; 82(1):65-9. PubMed ID: 21644473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of two multidrug regimens in multibacillary leprosy.
    Jadhav VH; Patki AH; Mehta JM
    Indian J Lepr; 1992; 64(4):501-4. PubMed ID: 1308526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short term combination therapy for paucibacillary leprosy--histological evaluation & follow-up study.
    Kumar B; Kaur S; Kaur I
    Indian J Lepr; 1987; 59(1):54-62. PubMed ID: 3302061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term follow up of multibacillary leprosy patients with high BI treated with WHO/MDT regimen for a fixed duration of two years.
    Shaw IN; Natrajan MM; Rao GS; Jesudasan K; Christian M; Kavitha M
    Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):405-9. PubMed ID: 11332283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative study of short term results in two multidrug regimens in multibacillary leprosy.
    Singh RP; Tiwari VD; Chattopadhyay SP
    Indian J Lepr; 1993; 65(2):173-80. PubMed ID: 8345231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Once monthly rifampicin (1200 mg) plus daily dapsone (100 mg) and clofazimine (100 mg) in the initial treatment of lepromatous leprosy.
    Chandorkar AG; Burte NP; Gade RK; Bulakh PM
    Indian J Lepr; 1984; 56(1):63-70. PubMed ID: 6384381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of rifampicin, clofazimine and dapsone in treating 296 cases of multibacillary leprosy].
    Li WZ
    Zhonghua Yi Xue Za Zhi; 1987 Jan; 67(1):1-3. PubMed ID: 3109697
    [No Abstract]   [Full Text] [Related]  

  • 39. Biochemical and hematological side effects of clofazimine in leprosy patients.
    Costa Queiroz RH; de Souza AM; Sampaio SV; Melchior E
    Pharmacol Res; 2002 Aug; 46(2):191-4. PubMed ID: 12220960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Multi-drug therapy trials for leprosy in Senegal: first observations relative to liver tolerance of multibacillary patients. Therapeutic consequences].
    Millan J; Roux G; Loko S; Naudin JC; Boucher P; Bodian M; Camara M; Moreira-Diop T; Grosset J
    Acta Leprol; 1986; 4(4):427-44. PubMed ID: 3296613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 80.